Final published version
Licence: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Osteonectin as a screening marker for pancreatic cancer
T2 - A prospective study
AU - Papapanagiotou, Angeliki
AU - Sgourakis, George
AU - Karkoulias, Kyriakos
AU - Raptis, Dimitris
AU - Parkin, Edward Thomas
AU - Brotzakis, Pantelis
AU - Panchal, Sanjay
AU - Papavassiliou, Athanasios
PY - 2018/7/1
Y1 - 2018/7/1
N2 - ObjectiveOsteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer.MethodsBlood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls.ResultsThe median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups.ConclusionOsteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies.
AB - ObjectiveOsteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer.MethodsBlood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls.ResultsThe median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups.ConclusionOsteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies.
KW - Osteonectin
KW - pancreatic cancer
KW - prospective study
KW - screening marker
KW - biomarkers
KW - adenocarcinoma
U2 - 10.1177/0300060518772413
DO - 10.1177/0300060518772413
M3 - Journal article
VL - 46
SP - 2769
EP - 2779
JO - Journal of International Medical Research
JF - Journal of International Medical Research
SN - 1473-2300
IS - 7
ER -